Jul. 21 at 12:58 PM
$RNTX Phase 2 RENEW trial now enrolling in all five planned countries with the opening of Germany, joining the US, UK, Australia, and Poland.
IPF is a rare disease, so more sites means more eligible patients and a faster path to an answer.
Heads-down on execution.
